Fusion Pharmaceuticals Acquires Investigational New Drug

Fusion Pharmaceuticals (Nasdaq: FUSN) has broadened its oncology pipeline with the acquisition of a Phase 2 program for a radiopharmaceutical targeting metastatic castrate resistant prostate cancer from RadioMedix, Inc.

The radiopharmaceutical, ²²⁵Ac-PSMA I&T, is a small molecule targeting prostate specific membrane antigen expressed on prostate cancers.

Highlights

• The Phase 2 “TATCIST” clinical trial is evaluating approximately 100 patients with metastatic castration-resistant prostate cancer with progressive disease.
• Efficacy will be assessed using change in PSA levels and radiographic response.
• Fusion expects to deliver topline data on 20-30 patients in Q1 2024.
• The company has also announced a $60 million private placement financing in connection with the transaction.

Fusion believes ²²⁵Ac-PSMA I&T will have the potential to target a growing patient population with significant unmet need.